Recent advances in the role of cortisol and metabolic syndrome in age-related degenerative diseases

Aging Clinical and Experimental Research

Volumn 28, Issue 1, 2016, Pages 17-23

  Martocchia, Antonio ^a   Stefanelli, Manuela ^a   Falaschi, Giulia Maria ^b   Toussan, Lavinia ^a   Ferri, Claudio ^b   Falaschi, Paolo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

11 Hydroxysteroid dehydrogenase type 1; Aging; Cortisol; Degenerative diseases; Metabolic syndrome

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; HYDROCORTISONE;

ABDOMINAL OBESITY; AGING; ATHEROSCLEROSIS; CHRONIC DISEASE; DEGENERATIVE DISEASE; DEMENTIA; DEPRESSION; ENZYME ACTIVITY; ESSENTIAL HYPERTENSION; FOLLOW UP; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; STRESS; AGED; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASE; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; METABOLISM;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; AGED; AGING; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DIABETES MELLITUS, TYPE 2; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; METABOLIC SYNDROME X; OBESITY, ABDOMINAL; PITUITARY-ADRENAL SYSTEM;

EID: 84962123155     PISSN: 15940667     EISSN: 17208319     Source Type: Journal    
DOI: 10.1007/s40520-015-0353-0     Document Type: Review

References (64)

1. Third Report of the National Cholesterol Education Program (NCEP) (2002) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). NIH Publication 2:1–284
2. Erkelens DW, de Bruin TWA, Cabezas MC (1993) Tulp syndrome. Lancet 342:1536–1537
3. Crepaldi G, Manzato E (1995) Polymetabolic syndrome. Minerva Endocrinol 20:155–160
4. Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of aWHO consultation. Diabet Med 15:539–553
5. Balkau B, Charles MA (1999) Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 16:442–443
6. Third Report of the National Cholesterol Education Program (NCEP) (2002) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106:3143–3421
7. Bloomgarden ZT (2003) American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome. Diabetes Care 26:1297–1303
8. Alberti KG, Zimmet P, Shaw J (2005) International Diabetes Federation (IDF) Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition. Lancet 366:1059–1062
9. Grundy SM, Cleeman JI, Daniels SR et al (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735–2752
10. Alberti KGMM, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome. A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645
11. Seth SM, Abd TT, Jones SR et al (2014) ACC/AHA Cholesterol treatment guideline. What was done well and what could be done better. J Am Coll Cardiol 63:2674–2678
12. Cornier MA, Dabelea D, Hernandez TL et al (2008) The metabolic syndrome. End Rev 29:777–822
13. Maggi S, Noale M, Zambon A et al (2008) Validity of the ATP III diagnostic criteria for the metabolic syndrome in an elderly Italian Caucasian population: the Italian Longitudinal Study on Aging. Atherosclerosis 197:877–882
14. Stefanelli M, Martocchia A, De Marinis EA et al (2013) Prevalence of metabolic syndrome in cognitive impairment. Aging Clin Exp Res 25:351–352
15. Egger G, Dixon J (2010) Obesity prevention. Inflammatory effects of nutritional stimuli: further support for the need for a big picture approach to tackling obesity and chronic disease. Obes Rev 11:137–149
16. Fehevari Z (2012) Focus on the inflammasome. An inflammatory assemblage. Nat Immunol 13:320
17. Després JP, Lemieux I, Bergeron J et al (2008) Cardiometabolic risk abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 28:1039–1049
18. Bjorntorp P (1991) Visceral fat accumulation: the missing link between psychosocial factors and cardiovascular disease? J Intern Med 230:195–201
19. Björntorp P (2001) Do stress reactions cause abdominal obesity and comorbidities? Obes Rev 2:73–86
20. Martocchia A, Curto M, Toussan L et al (2011) Pharmacological strategies against glucocorticoid-mediated brain damage during chronic disorders. Rec Patents CNS Drug Discov 6:196–204
21. Falaschi P, Martocchia A, Proietti A et al (1994) Immune system and the hypothalamus pituitary–adrenal axis. Common words for a single language. Ann N Y Acad Sci 29:89–111
22. McEwen BS, Gianaros PJ (2010) Central role of the brain in stress and adaptation: links to socioeconomic status, health, and disease. Ann N Y Acad Sci 1186:190–222
23. Charmandari E, Tsigos C, Chrousos G (2005) Endocrinology of the stress response. Annu Rev Physiol 67:259–284
24. Herman JP, Ostrander MM, Mueller NK et al (2005) Limbic system mechanisms of stress regulation: hypothalamo-pituitary adrenocortical axis. Prog Neuropsychopharmacol Biol Psychiatry 29:1201–1213
25. Peiffer A, Barden N, Meaney MJ (1991) Age-related changes in glucocorticoid receptor binding and mRNA levels in the rat brain and pituitary. Neurobiol Aging 12:475–479
26. Sapolsky RM, Krey LC, McEwen BS (1983) The adrenocortical stress-response in the aged male rat: impairment of recovery from stress. Exp Gerontol 18:55–64
27. Van Cauter E, Leproult R, Kupfer DJ (1996) Effects of gender and age on the levels and circadian rhythmicity of plasma cortisol. J Clin Endocr Metab 81:2468–2473
28. Falaschi P (1993) Neuroendocrinoimmunology. 94° Congr SIMI Ed Luigi Pozzi, Rome, pp 315–416
29. Tomlinson JW, Stewart PM (2004) “Cushing’s disease of the omentum”—fact or fiction? J Endocrinol Invest 27:171–174
30. Duclos M, Marquez Pereira P, Barat P et al (2005) Increased cortisol bioavailability, abdominal obesity, and the metabolic syndrome in obese women. Obes Res 13:1157–1166
31. Seeman TE, McEwen BS, Rowe JW et al (2001) Allostatic load as a marker of cumulative biological risk: MacArthur studies of successful aging. Proc Natl Acad Sci 98:4770–4775
32. Meco G, Formisano R, Falaschi P et al (1985) Dexamethasone non-suppressor Parkinsonian patients: a subgroup with depression and mental impairment. In: Burrows GD, Norman TR, Dennerstein L (eds) Clinical and pharmacological studies in psychiatric disorders. John Lippey, London, pp 171–185
33. Dekker MJ, Koper JW, Van Aken MO et al (2008) Salivary cortisol is related to atherosclerosis of carotid arteries. J Clin Endocrinol Metab 93:3741–3747
34. Chiodini I (2011) Diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab 96:1223–1236
35. Wirtz PH, Von Känel R, Emini L et al (2007) Evidence for altered hypothalamus–pituitary–adrenal axis functioning in systemic hypertension: blunted cortisol response to awakening and lower negative feedback sensitivity. Psychoneuroendocrinology 32:430–436
36. Gruenewald TL, Seeman TE, Karlamangla AS et al (2009) Allostatic load and frailty in older adults. J Am Geriatr Soc 57:1525–1531
37. Solfrizzi V, Scafato E, Frisardi V et al (2012) Frailty syndrome and all-cause mortality in demented patients: the Italian Longitudinal Study on Aging. Age (Dordr) 34:507–517
38. Waters DL, Qualls CR, Dorin RI et al (2008) Altered growth hormone, cortisol, and leptin secretion in healthy elderly persons with sarcopenia and mixed body composition phenotypes. J Gerontol A Biol Sci 63:536–541
39. Scafato E, Gandin C, Galluzzo L et al (2010) Prevalence of aging-associated cognitive decline in an Italian elderly population: results from cross-sectional phase of Italian PRoject on Epidemiology of Alzheimer’s disease (IPREA). Aging Clin Exp Res 22:440–449
40. Huang CW, Lui CC, Chang WN et al (2009) Elevated basal cortisol level predicts lower hippocampal volume and cognitive decline in Alzheimer’s disease. J Clin Neurosci 16:1283–1286
41. Raffaitin C, Tzourio C, Gin E et al (2009) Metabolic syndrome and risk for incident Alzheimer disease or vascular dementia: the three-city study. Diabetes Care 32:169–174
42. Vanhanen M, Koivisto K, Moilanen L et al (2006) Association of metabolic syndrome with Alzheimer disease: a population-based study. Neurology 67:843–847
43. Stefanelli M, Martocchia A, De Marinis EA et al (2014) Treatment of insulin resistance in the neurodegeneration. Recent Patents CNS Drug Discovery 9:54–63
44. Murakami H, Nigawara T, Sakihara S et al (2010) The frequency of type 2 diabetic patients who meet the endocrinological screening criteria of subclinical Cushing’s disease. Endocr J 57:267–272
45. Hamer M, O’Donnell K, Lahiri A et al (2010) Salivary cortisol responses to mental stress are associated with coronary artery calcification in healthy men and women. Eur Heart J 31:424–429
46. Dennison E, Hindmarsh P, Fall C et al (1999) Profiles of endogenous circulating cortisol and bone mineral density in healthy elderly men. J Clin Endocrinol Metab 84:3058–3063
47. Maggi S, Siviero P, Gonnelli S et al (2011) The burden of previous fractures in hip fracture patients. The Break Study. Aging Clin Exp Res 23:183–186
48. Zillikens MC, Uitterlinden AG, Van Leeuwen JP et al (2010) The role of body mass index, insulin, and adiponectin in the relation between fat distribution and bone mineral density. Calcif Tissue Int 86:116–125
49. Doherty TM, Asotra K, Fitzpatrick LA et al (2003) Calcification in atherosclerosis: bone biology and chronic inflammation at the arterial crossroads. Proc Natl Acad Sci USA 100:11201–11206
50. Helas S, Goettsch C, Schoppet M et al (2009) Inhibition of receptor activator of NF-kappa B ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol 175:473–478
51. Martocchia A, Toussan L, Stefanelli M et al (2011) Association of severity of osteoarthritis and carotid atherosclerosis in patients with metabolic syndrome. Rheumatol Open Access J 1:1–3
52. Stewart PM, Krozowski ZS (1999) 11β-Hydroxysteroid dehydrogenase. Vitam Horm 57:249–324
53. Basu R, Singh RJ, Basu A et al (2004) Splanchnic cortisol production occurs in humans evidence for conversion of cortisone to cortisol via the 11-β hydroxysteroid dehydrogenase (11β-HSD) type 1 pathway. Diabetes 53:2051–2059
54. Moisan MP, Seckl JR, Edwards CR (1990) 11β-Hydroxysteroid dehydrogenase bioactivity and messenger RNA expression in rat forebrain: localization in hypothalamus, hippocampus, and cortex. Endocrinology 127:1450–1455
55. Veilleux A, Rhéaume C, Daris M et al (2009) Omental adipose tissue type 1 11beta-hydroxysteroid dehydrogenase oxoreductase activity, body fat distribution, and metabolic alterations in women. J Clin Endocrinol Metab 94:3550–3557
56. Wake DJ, Rask E, Livingstone DE et al (2003) Local and systemic impact of transcriptional up-regulation of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. J Clin Endocrinol Metab 88:3983–3988
57. Cooper MS, Rabbitt EH, Goddard PE et al (2002) Osteoblastic 11beta-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure. J Bone Miner Res 17:979–986
58. Morton NM, Paterson JM, Masuzaki H et al (2004) Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11β-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 53:931–938
59. Martocchia A, Stefanelli M, Falaschi GM et al (2013) Targets of anti-glucocorticoid therapy for stress-related disease. Recent Patents CNS Drug Discov 8:79–87
60. Alberts P, Engblom L, Edling N et al (2002) Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 45:1528–1532
61. Hermanowski-Vosatka A, Balkovec JM, Cheng K et al (2005) 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med 202:517–527
62. Rosenstock J, Bananer S, Fonseca VA et al (2010) The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled Bb metformin monotherapy. Diabetes Care 33:1516–1522
63. Feig PU, Shah S, Hermanowski-Vosatka A et al (2011) Effects of an 11-betahydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes Obes Metab 13:498–504
64. Shah S, Hermanowski-Vosatka A, Gibson K et al (2011) Efficacy and safety of the selective 11β-HSD1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension. J Am Soc Hypertension 5:166–176